ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MRSN Mersana Therapeutics Inc

5.31
0.46 (9.48%)
Pre Market
Last Updated: 07:52:11
Delayed by 15 minutes

Period:

Draw Mode:

Volume 30,664
Bid Price 5.14
Ask Price 5.32
News -
Day High

Low
0.8014

52 Week Range

High
9.62

Day Low
Company Name Stock Ticker Symbol Market Type
Mersana Therapeutics Inc MRSN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.46 9.48% 5.31 07:52:11
Open Price Low Price High Price Close Price Prev Close
4.85
Trades Volume Avg Volume 52 Week Range
157 30,664 - 0.8014 - 9.62
Last Trade Time Type Quantity Stock Price Currency
07:52:08 formt 510 $ 5.31 USD

Mersana Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
584.82M 120.58M - 26.58M -204.21M -1.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Mersana Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MRSN Message Board. Create One! See More Posts on MRSN Message Board See More Message Board Posts

Historical MRSN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.635.0153.634.222,083,5051.6846.28%
1 Month3.175.0153.153.902,114,1832.1467.51%
3 Months2.215.0151.883.151,850,8643.10140.27%
6 Months1.235.0151.0652.112,084,4094.08331.71%
1 Year5.839.620.80142.653,391,480-0.52-8.92%
3 Years18.7020.280.80144.431,861,882-13.39-71.60%
5 Years6.9129.090.80146.891,419,270-1.60-23.15%

Mersana Therapeutics Description

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

Your Recent History

Delayed Upgrade Clock